85
Participants
Start Date
October 31, 2008
Primary Completion Date
September 30, 2009
Study Completion Date
October 31, 2009
Truvada + Kaletra
Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
Kivexa + Kaletra
Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
Gilead Sciences, Vienna
Gilead Sciences, Munich
Gilead Sciences, Milan
Gilead Sciences, Madrid
Lead Sponsor
Gilead Sciences
INDUSTRY